Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D54QKH
|
|||
| Drug Name |
Mezagitamab
|
|||
| Synonyms |
TAK-079
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Myasthenia gravis [ICD-11: 8C6Y] | Phase 2 | [1] | |
| Primary immune thrombocytopenia [ICD-11: 3B64.10] | Phase 2 | [2] | ||
| IgA nephropathy [ICD-11: MF8Y] | Phase 1 | [3] | ||
| Company |
TAKEDA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclic ADP-ribose hydrolase 1 (CD38) | Target Info | . | [4] |
| KEGG Pathway | Nicotinate and nicotinamide metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Oxytocin signaling pathway | ||||
| Salivary secretion | ||||
| Pancreatic secretion | ||||
| Epstein-Barr virus infection | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Panther Pathway | CCKR signaling map ST | |||
| WikiPathways | Oxytocin signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04159805) A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04278924) A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia. U.S.National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT05174221) A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy. U.S.National Institutes of Health. | |||
| REF 4 | Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. Br J Clin Pharmacol. 2020 Jul;86(7):1314-1325. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.